WIB22: Amber Salzman had few options when her son was diagnosed with a rare genetic disease. So she created a better one
This profile is part of Endpoints News’ 2022 special report about Women in Biopharma R&D. You can read the full report here.
Amber Salzman’s life changed on a cold, damp day in Paris over tiny plastic cups of lukewarm tea.
She was meeting with Patrick Aubourg, a French neurologist studying adrenoleukodystrophy, or ALD, a rare genetic condition that causes rapid neurological decline in young boys. It’s a sinister disease that often leads to disability or death within just a few years. Salzman’s nephew was diagnosed at just 6 or 7 years old, and died at the age of 12.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
